Cellectis S.A. (ADR)
General ticker "CLLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $211.8M (TTM average)
Cellectis S.A. (ADR) follows the US Stock Market performance with the rate: 56.2%.
Estimated limits based on current volatility of 3.5%: low 4.18$, high 4.49$
Factors to consider:
- Total employees count: 116 as of 2015
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.79$, 6.47$]
- 2026-12-31 to 2027-12-31 estimated range: [2.37$, 5.52$]
Financial Metrics affecting the CLLS estimates:
- Positive: with PPE of -6.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -8.67 <= 0.07
- Positive: 19.49 < Shareholder equity ratio, % of 23.37 <= 42.60
- Negative: negative Net income
- Negative: Inventory ratio change, % of 16.04 > 0.80
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
Short-term CLLS quotes
Long-term CLLS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.76MM | $41.51MM | $73.17MM |
| Operating Expenses | $98.06MM | $101.06MM | $113.66MM |
| Operating Income | $-97.30MM | $-59.55MM | $-40.48MM |
| Non-Operating Income | $-19.16MM | $22.79MM | $-34.41MM |
| Interest Expense | $5.31MM | $7.45MM | $8.13MM |
| R&D Expense | $87.65MM | $90.54MM | $93.81MM |
| Income(Loss) | $-116.46MM | $-36.76MM | $-74.89MM |
| Taxes | $-0.37MM | $0.00MM | $-7.09MM |
| Profit(Loss)* | $-101.06MM | $-36.83MM | $-67.80MM |
| Stockholders Equity | $84.69MM | $131.03MM | $75.90MM |
| Assets | $334.27MM | $383.54MM | $324.72MM |
| Operating Cash Flow | $-24.75MM | $22.10MM | $-40.14MM |
| Capital expenditure | $1.07MM | $2.58MM | $2.37MM |
| Investing Cash Flow | $-15.51MM | $-102.63MM | $-29.58MM |
| Financing Cash Flow | $82.86MM | $89.80MM | $-16.20MM |
| Earnings Per Share** | $-1.77 | $-0.41 | $-0.68 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.